This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
DBN1 / Drebrin · IHC design guide
Design Immunohistochemistry for DBN1
Plan chromogenic DBN1 IHC in paraffin sections using cerebellar granular-layer processes as a strong-staining reference (HPA tissue IHC). The guide covers fixation consistency, staining expectations and how to interpret weaker hippocampal neuronal staining (HPA tissue IHC).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
DBN1 Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Cytoplasmic and membranous tissue staining (HPA tissue IHC) | |
| Staining pattern | Strong staining in cerebellar granular-layer processes (HPA tissue IHC) | |
| Antigen retrieval | EDTA pH 8.0 HIER, heat-mediated (datasheet A05530-1) | |
| Positive control | Cerebellum+4 more · see all | |
| Negative control | Adipose tissue+4 more · see all |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Keep fixation consistent across sections (standard IHC practice; not target-specific). Selected-image fixative and duration unreported (datasheet A05530-1); verify before use. | |
| Caveat | Hippocampal neurons stain low despite high cerebellar processes (HPA tissue IHC) | |
| Regulation | Intensity regulation is unspecified (UniProt) | |
| Isoform / epitope | 3 isoforms; isoform-specific epitope coverage is unknown (UniProt) |
Section 1
Recommended DBN1 IHC & IF Protocols
The catalog antibody’s IHC protocol uses EDTA pH 8.0 heat retrieval (datasheet: A05530-1). The published options below report only the IHC steps stated in each article (PMC12262305; PMC7352383).
| Sample | Paraffin-embedded human laryngeal carcinoma tissue; fixative not specified (datasheet A05530-1) |
| Fixation | Image fixative and duration unreported (datasheet A05530-1); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat retrieval: EDTA pH 8.0 (datasheet A05530-1); 20 min, 95–100 °C (standard) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% goat serum (datasheet A05530-1) |
| Primary antibody | Rabbit anti-DBN1, 2-5 μg/ml (datasheet A05530-1) |
| Primary incubation | Overnight at 4 °C (datasheet A05530-1) |
| Detection | Streptavidin-biotin complex (SABC), DAB chromogen (datasheet A05530-1) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | DBN1-positive staining in processes in granular layer of cerebellum (HPA tissue IHC: High). HPA tissue profile: Cytoplasmic and membranous expression in several tissues, most abundant in CNS. No signal in the no-primary control. |
💡Decision noteStart with EDTA pH 8.0 heat retrieval for the catalog antibody (datasheet: A05530-1); neither published excerpt specifies a retrieval condition (PMC12262305; PMC7352383).
Section 2
What Is the Expected DBN1 Staining Pattern?
DBN1 is a cytoplasmic, cortical and cell projection protein with no transmembrane segment (UniProt Q16643). In paraffin-section IHC, expect cytoplasmic or membranous staining, most abundant in CNS tissue (HPA tissue IHC: Enhanced). Examine neuronal processes and neuropil as well as cell bodies: HPA reports high staining in cerebellar granular-layer processes, medium staining in cerebral cortical neuropil and low staining in hippocampal neuronal cells (HPA tissue IHC).
| Cerebellar granular-layer processes stain strongly; cerebral cortical neuropil stains less strongly (HPA tissue IHC). | This distribution fits HPA's high cerebellar process and medium cortical neuropil observations (HPA tissue IHC). Assess the named structures separately from neighboring cells; a section-wide intensity judgment can obscure the expected pattern. UniProt also places DBN1 in dendrites, the cell cortex and growth cones (UniProt Q16643). |
| The dominant signal is confined to nuclei or appears as a sharply extracellular deposit. | That compartment does not fit the reported cytoplasmic, projection and junction locations (UniProt Q16643), or HPA's cytoplasmic and membranous tissue profile (HPA tissue IHC). Treat it as suspect until controls and tissue morphology support it; a compartment mismatch alone does not identify the source of artefact (standard IHC interpretation). |
| Signal appears in adipocytes or cardiomyocytes, while expected positive structures stain poorly (HPA tissue IHC). | HPA reports DBN1 as not detected in those particular cell populations (HPA tissue IHC). Investigate cross-reactivity or endogenous detection activity before assigning the signal to DBN1 (standard IHC practice). A negative HPA entry concerns the specified cell type; it does not establish that every cell in that tissue is negative. |
| Uniform chromogen covers cells, stroma and otherwise pale areas, obscuring structure. | A broad haze is difficult to reconcile with HPA's cell-specific staining levels and cytoplasmic or membranous profile (HPA tissue IHC). Consider nonspecific binding, endogenous detection activity or excess chromogen development (standard IHC practice). Judge specificity from recognizable cells and compartments rather than overall slide darkness. |
| No signal appears in cerebellar granular-layer processes (HPA tissue IHC). | This misses an HPA high reference pattern, so interpret other negative fields cautiously (HPA tissue IHC). Check section integrity and the staining run before concluding DBN1 is absent (standard IHC practice). HPA's Enhanced reliability describes agreement between staining and RNA data; it does not guarantee that every specimen or run will stain. |
💡Expected DBN1 appearanceCall positive IHC when high signal outlines cerebellar granular-layer processes in a cytoplasmic or projection pattern (HPA tissue IHC; UniProt Q16643); nuclear-only staining or indiscriminate chromogen is suspect (standard IHC interpretation).
| Cell and tissue choice | Use cerebellar granular-layer processes as a strong pattern reference; HPA scores them high, whereas hippocampal neuronal cells are low (HPA tissue IHC). A weak hippocampal result therefore has less power to diagnose a failed run. UniProt reports expression in hippocampal regions (UniProt Q16643); that statement does not override HPA's cell-specific IHC score. |
| Antibody evidence | HPA rates tissue IHC reliability Enhanced and lists 2 rabbit polyclonal antibodies, HPA051452 and HPA056940, with Enhanced IHC validation (HPA tissue IHC; HPA antibodies). These observations support the reference pattern but do not validate an unspecified antibody, dilution or detection system. |
| Epitope and molecular form | UniProt lists 3 isoforms, a chain spanning residues 2–649, an ADF-H domain at 3–134 and multiple modified residues (UniProt Q16643). Epitope location for the antibody used here is unreported; these features cannot predict which isoforms it detects or whether retrieval changes its signal. |
| IF/ICC Q&A: where should cellular signal appear? | HPA's ICC-IF summary places DBN1 mainly at the plasma membrane, with additional actin-filament localization (HPA subcellular ICC-IF). UniProt also reports cytoplasmic and cell-cortex locations (UniProt Q16643). This answers cellular localization only; ICC-IF observations do not set a paraffin-section IHC staining score or an IF protocol. |
| Situation | Likely cause | Next action |
|---|---|---|
| No staining in the chosen test tissue. | The selected cell population may have a weak reference pattern: hippocampal neuronal cells are low by HPA IHC (HPA tissue IHC). | Review a cerebellar section containing granular-layer processes, scored high by HPA (HPA tissue IHC). If that reference also fails, check reagent integrity, detection steps and section quality (standard IHC practice); do not infer DBN1 absence from an unverified run. |
| Cerebellar processes are present but unstained. | A failed staining step or unsuitable assay conditions are possibilities (standard IHC practice); the payload gives no DBN1-specific fixation sensitivity or retrieval requirement. | Confirm tissue morphology and the run controls, then review the antibody's documented IHC conditions and the retrieval and detection steps used (standard IHC practice). Record any adjustment as assay optimization, without claiming that fixation masked a DBN1 epitope. |
| Strong nuclear-only staining dominates. | Nuclear restriction conflicts with UniProt's cytoplasmic, cortical and projection locations and HPA's tissue profile (UniProt Q16643; HPA tissue IHC). | Inspect morphology, compare expected positive structures and repeat with appropriate negative controls (standard IHC practice). If available, compare an independently validated antibody; HPA lists 2 antibodies with Enhanced IHC validation (HPA antibodies). |
| Chromogen appears in HPA-negative cell populations. | Cross-reactivity or endogenous detection activity may explain staining in adipocytes or cardiomyocytes, both not detected by HPA IHC (HPA tissue IHC; standard IHC practice). | Check a no-primary control and any detection-system controls appropriate to the run, then reassess the exact cell type (standard IHC practice). Do not extend a cell-specific HPA negative call to the entire tissue. |
| Diffuse background hides cell boundaries. | Nonspecific binding, incomplete blocking or detection background can reduce contrast (standard IHC practice); HPA does not establish a DBN1-specific cause. | Review blocking, washing, primary-antibody concentration and chromogen development against the run controls (standard IHC practice). Score only clearly localized signal after background is controlled, using the cytoplasmic and membranous HPA pattern as a reference (HPA tissue IHC). |
Experiment evidence
IHC & IF images showing DBN1 staining
A05530-1 · IHCIHC analysis of Drebrin/DBN1 using anti-Drebrin/DBN1 antibody (A05530-1). Drebrin/DBN1 was detected in a paraffin-embedded section of human
A05530-1 · IHCIHC analysis of Drebrin/DBN1 using anti-Drebrin/DBN1 antibody (A05530-1). Drebrin/DBN1 was detected in a paraffin-embedded section of human
A05530-1 · IFIF analysis of Drebrin/DBN1 using anti-Drebrin/DBN1 antibody (A05530-1). Drebrin/DBN1 was detected in an immunocytochemical section of CACO-
M05530-4 · IHCIHC analysis of DBN1 using anti-DBN1 antibody (M05530-4). DBN1 was detected in a paraffin-embedded section of human ovarian serous carcinoma
M05530-4 · IHCIHC analysis of DBN1 using anti-DBN1 antibody (M05530-4). DBN1 was detected in a paraffin-embedded section of human thyroid cancer tissue. H
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000113758-DBN1/tissue/cerebral+cortex#imid_16022339
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000113758-DBN1/tissue/colon#imid_16022265
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000113758-DBN1/tissue/liver#imid_16022274
HPA · GallbladderHuman Protein Atlas IHC, Gallbladder. Source: https://www.proteinatlas.org/ENSG00000113758-DBN1/tissue/gallbladder#imid_16022250
HPA · ICC-IF HeLaHuman Protein Atlas immunofluorescence, HeLa, antibody HPA051452; green = DBN1, blue = nucleus, red = microtubules.
HPA · ICC-IF HeLaHuman Protein Atlas immunofluorescence, HeLa, antibody HPA051452; green = DBN1, blue = nucleus, red = microtubules.
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for DBN1 IHC & IF
🧪Run cerebellum first and confirm staining in processes of the granular layer (HPA: High in processes in the cerebellar granular layer). Use adipose tissue as the negative tissue; adipocytes are listed as not detected (HPA: Not detected in adipocytes). Within the cerebellar section, nuclei should lack specific chromogen while the labeled processes remain distinct (HPA: staining in processes; UniProt Q16643: cytoplasmic and cell-projection localization).
Positive control tissue: Cerebellum (Processes in granular layer, HPA High)
Negative control tissue: Adipose tissue (HPA Not detected)
ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show DBN1 in HeLa, PC-3, U2OS, KOLF2.1J, with annotated localisation: Plasma membrane (approved) (HPA subcellular).
Technical controls: Include a no-primary, secondary-only slide, a nonimmune IgG control matched to the primary antibody’s host species and clonality, and DBN1 knockout material processed in parallel if available (standard IHC controls). Quench endogenous peroxidase and control endogenous biotin when using the caption’s biotin-based DAB detection (caption: biotinylated secondary, streptavidin–biotin complex and DAB); check cerebellar autofluorescence if evaluating an IF slide (standard IHC/IF practice).
⚠️Feasibility: A target-specific fixation window or fixation effect is unreported in the supplied evidence, and the selected A05530-1 tissue-IHC caption does not state a fixative (caption: fixative not stated). The paraffin-section example used heat retrieval in EDTA at pH 8.0, so that is a documented starting condition, not evidence that retrieval is universally required (caption: heat-mediated EDTA retrieval). The supplied evidence does not establish that frozen sections or IF are easier for DBN1; in cerebellum, assess fine process staining against background carefully (HPA: High in processes in the granular layer).
HPA tissue IHC evidence for DBN1
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Enhanced — High consistency between antibody staining and RNA expression data.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Cerebellum | Processes in granular layer | High | Protein (IHC) | HPA → |
| Testis | Spermatogonia cells | High | Protein (IHC) | HPA → |
| Cerebral cortex | Neuropil | Medium | Protein (IHC) | HPA → |
| Endometrium | Cells in endometrial stroma | Medium | Protein (IHC) | HPA → |
| Epididymis | Glandular cells | Medium | Protein (IHC) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adipose tissue | Adipocytes | Not detected | Protein (IHC) | HPA → |
| Adrenal gland | Glandular cells | Not detected | Protein (IHC) | HPA → |
| Appendix | Endocrine cells | Not detected | Protein (IHC) | HPA → |
| Bronchus | Respiratory epithelial cells | Not detected | Protein (IHC) | HPA → |
| Cervix | Glandular cells | Not detected | Protein (IHC) | HPA → |
Section 3
Advanced DBN1 IHC Tips
Troubleshoot DBN1 staining in paraffin sections by checking retrieval, detection, and the expected cellular pattern before comparing samples.
What retrieval should I try first when DBN1 staining is weak?
For paraffin sections, start with heat-mediated retrieval in EDTA at pH 8.0 (datasheet A05530-1). The documented tissue stain used this retrieval before an overnight incubation at 4°C with 2 μg/ml primary antibody (caption A05530-1). If signal remains weak, first check heating consistency, section adhesion, and primary-antibody coverage while keeping the documented retrieval constant (standard IHC practice). Only then compare an alternative retrieval condition on adjacent sections, judging signal against tissue morphology and background; the caption provides no evidence that another buffer or pH improves DBN1 detection (caption A05530-1; standard IHC practice).
Could fixation explain inconsistent DBN1 staining between paraffin blocks?
Possibly, but target-specific fixation sensitivity is unknown: the selected paraffin-section caption does not state the fixative (caption A05530-1). Record each block’s fixation history, section thickness, and storage conditions, then compare blocks using the same EDTA pH 8.0 retrieval and 2 μg/ml primary concentration (datasheet A05530-1; caption A05530-1; standard IHC practice). Include a consistently processed reference section in each run so changes in detection do not masquerade as block effects (standard IHC practice). Do not infer DBN1 fixation tolerance from its actin-associated localisation or reported phosphorylation sites; neither establishes how this antibody’s epitope survives fixation (UniProt Q16643; caption A05530-1).
Where should convincing DBN1 chromogenic staining appear?
Assess staining in the cytoplasm, cell cortex, and cellular projections, where DBN1 is reported to localize (UniProt Q16643). In neural tissue, examine processes in the cerebellar granular layer and cortical neuropil as spatial references, while accounting for the reported differences in staining level between those sites (HPA: High in cerebellar granular-layer processes; Medium in cerebral-cortex neuropil). Membranous staining can also fit the reported tissue profile, but DBN1 has no transmembrane segment, so a crisp membrane outline alone deserves scrutiny (HPA tissue IHC; UniProt Q16643 topology; standard IHC practice). Compare the pattern with cell morphology and a counterstain rather than scoring all brown deposits as equivalent (standard IHC practice).
How can isoforms or epitope uncertainty affect DBN1 IHC interpretation?
DBN1 has 3 annotated isoforms, but the supplied caption does not map the A05530-1 epitope or establish which isoforms it detects (UniProt Q16643; caption A05530-1). Its ADF-H domain spans residues 3–134, and reported phosphorylation includes residues 141, 142, 331, and 335 (UniProt Q16643). These features identify questions to investigate if staining differs between samples; they do not establish that any isoform or modification causes a particular IHC pattern (UniProt Q16643; standard IHC practice). Keep retrieval and detection conditions matched, and seek epitope mapping or an independent antibody before assigning a staining difference to an isoform (standard IHC practice).
How should an IF experiment help assess a disputed DBN1 IHC pattern?
On the separate IF/ICC workflow, multiplex DBN1 with a marker of the expected cell type so that apparent signal can be assigned to the appropriate cells and processes (standard IF practice; HPA tissue IHC). Choose a fluorophore channel after inspecting unstained tissue for autofluorescence, and include single-label controls to check bleed-through (standard IF practice). Because DBN1 is cytoplasmic and actin-associated with no transmembrane segment, permeabilisation may be needed to expose an intracellular epitope, although this antibody’s epitope is unspecified (UniProt Q16643; HPA subcellular; caption A05530-1). HPA IF localisation at the plasma membrane and actin filaments offers a comparison, but does not validate the catalog antibody for IF (HPA subcellular; caption A05530-1).
How can I reduce diffuse brown background without losing DBN1 signal?
Reproduce the documented 10% goat-serum block and 2 μg/ml primary incubation overnight at 4°C before changing several variables at once (caption A05530-1). Run a no-primary section to assess secondary-reagent and detection background, and apply an endogenous-peroxidase block where appropriate for DAB detection (standard IHC practice; caption A05530-1: DAB detection). If background persists, compare a primary-antibody dilution series on adjacent sections while preserving EDTA pH 8.0 retrieval (datasheet A05530-1; standard IHC practice). Judge improvement by retained cellular and process-associated signal against reduced staining in tissue regions that should be negative, rather than by overall slide brightness alone (UniProt Q16643; standard IHC practice).
What should I measure when comparing DBN1 staining across sections? ⚠ ANSWER MARKED FOR VERIFICATION
Choose the measurement around the structure of interest: use an H-score or percentage of positive cells for identifiable cell populations, and positive-process area or density per mm² for neuropil or projection-rich regions (standard IHC practice; UniProt Q16643). Define a consistent tissue compartment and threshold before reviewing groups, then normalize counts to eligible cells or measurements to evaluable tissue area (standard IHC practice). Keep staining runs, imaging settings, and exclusion criteria consistent, particularly when comparing cerebellar processes with cortical neuropil (standard IHC practice; HPA tissue IHC). Report cell-body and process staining separately when they convey different spatial information, and exclude folds, edges, and necrotic regions from scored area (standard IHC practice).
How do I distinguish true DBN1 staining from artefact?
A credible pattern follows cells or projections consistent with cytoplasmic, cortical, and junction-associated DBN1, rather than isolated precipitate or staining confined to cut edges (UniProt Q16643; standard IHC practice). Check cell identity: HPA reports High staining in cerebellar granular-layer processes and spermatogonia, while adipocytes and cardiomyocytes are reported as Not detected (HPA tissue IHC). Treat signal concentrated in necrotic areas, folds, or edges as suspect, and compare it with a no-primary control for endogenous-enzyme or detection artefact (standard IHC practice). Finally, interpret a membrane outline alongside cytoplasmic or process signal and morphology, since DBN1 has no transmembrane segment despite reported membranous staining (UniProt Q16643 topology; HPA tissue IHC).
Boster reagents
Best DBN1 / Drebrin IHC Antibodies
The catalog shows paraffin-section IHC images from human tissue and rat brain (IHC image captions), plus an IF image from CACO-2 cells (A05530-1 IF image caption).
Real IHC data
Anti-Drebrin/DBN1 Antibody ®
Cat # A05530-1
Real IHC data
Anti-Drebrin/DBN1 Antibody ® (monoclonal, 4F6E7)
Cat # M05530-4
A05530-1 has IHC images from human laryngeal carcinoma and cerebellum (A05530-1 IHC image captions) and an IF image from CACO-2 cells (A05530-1 IF image caption). M05530-4 has IHC images from human ovarian serous carcinoma and rat brain (M05530-4 IHC image captions).
Which to pick: For paraffin-section IHC, choose A05530-1 for a rabbit primary or M05530-4 for a mouse monoclonal primary (catalog hosts and clone; each SKU’s IHC image captions); both captions report EDTA retrieval at pH 8.0, while fixation is unreported (IHC image captions). For IF/ICC, choose A05530-1: IF and ICC are listed applications, with a CACO-2 IF image at 5 μg/ml (A05530-1 catalog applications and IF image caption). For cross-species tissue work, M05530-4 lists human, mouse, rat and monkey reactivity, with IHC images for human and rat; A05530-1 lists human, rat and monkey reactivity, with IHC images for human (catalog reactivity; each SKU’s IHC image captions).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry Q16643 (DREB_HUMAN, Drebrin).
- Human Protein Atlas. DBN1 tissue IHC expression (reliability: Enhanced).
- Human Protein Atlas. DBN1 subcellular location (ICC-IF): Mainly localized to the plasma membrane. In addition localized to the actin filaments..
- Human Protein Atlas. DBN1 antibody validation summary (2 antibodies).
- Elevated Plasma Levels of Drebrin in Glaucoma Patients With Neurodegeneration. Frontiers in neuroscience 2019 — PMC6456690.
- Integrated Spatial Analysis of Ovarian Precancerous Lesions. bioRxiv : the preprint server for biology 2025 — PMC12262305.
- Integrated Analysis of Key Differentially Expressed Genes Identifies DBN1 as a Predictive Marker of Response to Endocrine Therapy in Luminal Breast Cancer. Cancers 2020 — PMC7352383.
- Gut microbiota of the young ameliorates physical fitness of the aged in mice. Microbiome 2022 — PMC9791737.
- PubMed PMID:8216329 — UniProt-cited evidence.
- PubMed PMID:14702039 — UniProt-cited evidence.
- PubMed PMID:17974005 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for DBN1 (Drebrin). Expected localisation Cytoplasmic and membranous tissue staining (HPA tissue IHC). Antigen retrieval: EDTA pH 8.0 HIER, heat-mediated (datasheet A05530-1). Validated IHC antibody: A05530-1 at 2-5 μg/ml (the product's own IHC validation image is shown). Controls (HPA): positive Cerebellum (Processes in granular layer); negative Adipose tissue. IHC-P workflow on paraffin sections; fixative unspecified. Protocol steps: 1. Sample: Paraffin-embedded human laryngeal carcinoma tissue; fixative not specified (datasheet A05530-1); 2. Fixation: Image fixative and duration unreported (datasheet A05530-1); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat retrieval: EDTA pH 8.0 (datasheet A05530-1); 20 min, 95–100 °C (standard); 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% goat serum (datasheet A05530-1); 8. Primary antibody: Rabbit anti-DBN1, 2-5 μg/ml (datasheet A05530-1); 9. Primary incubation: Overnight at 4 °C (datasheet A05530-1). Watch for: Fixation: Keep fixation consistent across sections (standard IHC practice; not target-specific). Selected-image fixative and duration unreported (datasheet A05530-1); verify before use.; Caveat: Hippocampal neurons stain low despite high cerebellar processes (HPA tissue IHC); Isoform / epitope: 3 isoforms; isoform-specific epitope coverage is unknown (UniProt); Regulation: Intensity regulation is unspecified (UniProt). Evidence: UniProt Q16643, HPA tissue IHC · Enhanced, HPA ICC-IF · Mainly localized to the plasma membrane. In addition localized to…, Datasheet A05530-1, PMC12262305, PMC7352383. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/DBN1/immunohistochemistry-ihc-guide.